Page last updated: 2024-12-06

1,2,3,4-tetrachlorodibenzodioxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1,2,3,4-Tetrachlorodibenzodioxin (TCDD)

1,2,3,4-Tetrachlorodibenzodioxin (TCDD) is a highly toxic and persistent environmental contaminant. It's a member of a family of compounds known as **dioxins**, which are formed as byproducts of industrial processes such as waste incineration, chemical manufacturing, and paper bleaching.

**Why it's important for research:**

* **Highly Toxic:** TCDD is one of the most toxic substances known to humans. It has been linked to a range of health problems, including cancer, immune system suppression, reproductive issues, and developmental defects.
* **Persistent in the Environment:** TCDD is very stable and persistent in the environment, meaning it breaks down very slowly. This means it can accumulate in the food chain and pose a long-term risk to human health.
* **Model for Understanding Toxicity:** TCDD serves as a model compound for studying the mechanisms of dioxin toxicity. Research on TCDD has helped scientists understand how dioxins interact with cellular processes and how they can cause disease.
* **Environmental Monitoring:** TCDD levels are monitored in the environment to assess exposure risk and track the effectiveness of pollution control measures.
* **Drug Development:** Research on TCDD has led to the development of drugs that can block the effects of dioxins and other toxic compounds.

**Specific Research Areas:**

* **Mechanism of Toxicity:** Research focuses on how TCDD binds to the aryl hydrocarbon receptor (AhR), a protein that plays a critical role in regulating gene expression and mediating the toxic effects of dioxins.
* **Biomarkers of Exposure:** Scientists are working to develop reliable biomarkers that can detect TCDD exposure and assess the risk of health problems.
* **Risk Assessment:** Researchers are studying the long-term health effects of TCDD exposure and developing models to predict the risks associated with different levels of exposure.
* **Remediation and Detoxification:** Scientists are working to develop methods to remove TCDD from the environment and to detoxify it in the body.

**Overall, research on TCDD is crucial for understanding the environmental and health risks associated with this potent contaminant and developing strategies to minimize its impact.**

1,2,3,4-tetrachlorodibenzodioxin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID35454
CHEMBL ID343583
CHEBI ID27785
SCHEMBL ID652558
MeSH IDM0243316

Synonyms (30)

Synonym
1,2,3,4-tetrachlorodibenzo-para-dioxin
CHEBI:27785 ,
1,2,3,4-tetrachlorodibenzo[b,e][1,4]dioxin
1,2,3,4-tetrachlorodibenzodioxine
1,2,3,4-tetrachlorooxanthrene
dibenzo[b,e][1,4]dioxin, 1,2,3,4-tetrachloro-
dibenzo-p-dioxin, 1,2,3,4-tetrachloro-
dibenzo(b,e)(1,4)dioxin, 1,2,3,4-tetrachloro-
brn 1323932
1,2,3,4-tcdd
30746-58-8
1,2,3,4-tetrachlorodibenzo-p-dioxin
1,2,3,4-tetrachlorodibenzodioxin
STK132073
1,2,3,4-tetrachloro-dibenzo[1,4]dioxine
CHEMBL343583 ,
AKOS005403492
unii-hf5s8p28cc
hf5s8p28cc ,
bdbm50408319
pcdd 27
SCHEMBL652558
DJHHDLMTUOLVHY-UHFFFAOYSA-N
1,2,3,4-tetrachlorooxanthrene #
DTXSID7074030
tegaserodmaleate
1,2,3,4-tetrachlorodibenzo[b,e][1,4]dioxine
Q27103331
two column dioxin & furan sampling spike (13c12, 99%) in nonane
1,2,3,4-tetrachloro-dibenzo-p-dioxin
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
polychlorinated dibenzodioxineAny dibenzodioxine in which two or more hydrogens have been replaced by chlorines.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A1Rattus norvegicus (Norway rat)EC50 (µMol)1.30020.00152.205710.0000AID39064
Aryl hydrocarbon receptorHomo sapiens (human)EC50 (µMol)1.30020.00151.976910.0000AID39064
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
blood vessel developmentAryl hydrocarbon receptorHomo sapiens (human)
regulation of adaptive immune responseAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of T cell mediated immune response to tumor cellAryl hydrocarbon receptorHomo sapiens (human)
regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
xenobiotic metabolic processAryl hydrocarbon receptorHomo sapiens (human)
apoptotic processAryl hydrocarbon receptorHomo sapiens (human)
response to xenobiotic stimulusAryl hydrocarbon receptorHomo sapiens (human)
response to toxic substanceAryl hydrocarbon receptorHomo sapiens (human)
regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
cAMP-mediated signalingAryl hydrocarbon receptorHomo sapiens (human)
intracellular receptor signaling pathwayAryl hydrocarbon receptorHomo sapiens (human)
regulation of B cell proliferationAryl hydrocarbon receptorHomo sapiens (human)
circadian regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of inflammatory responseAryl hydrocarbon receptorHomo sapiens (human)
cellular response to molecule of bacterial originAryl hydrocarbon receptorHomo sapiens (human)
cellular response to cAMPAryl hydrocarbon receptorHomo sapiens (human)
cellular response to forskolinAryl hydrocarbon receptorHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxineAryl hydrocarbon receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
transcription cis-regulatory region bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAryl hydrocarbon receptorHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
TFIID-class transcription factor complex bindingAryl hydrocarbon receptorHomo sapiens (human)
transcription coactivator bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activityAryl hydrocarbon receptorHomo sapiens (human)
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
protein bindingAryl hydrocarbon receptorHomo sapiens (human)
TBP-class protein bindingAryl hydrocarbon receptorHomo sapiens (human)
protein homodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
protein heterodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
Hsp90 protein bindingAryl hydrocarbon receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAryl hydrocarbon receptorHomo sapiens (human)
E-box bindingAryl hydrocarbon receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nuclear aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nucleoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytosolAryl hydrocarbon receptorHomo sapiens (human)
chromatinAryl hydrocarbon receptorHomo sapiens (human)
transcription regulator complexAryl hydrocarbon receptorHomo sapiens (human)
protein-containing complexAryl hydrocarbon receptorHomo sapiens (human)
cytosolic aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID39064Affinity on cytosolic Aromatic hydrocarbon receptor (Ah)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (31.58)18.2507
2000's7 (36.84)29.6817
2010's6 (31.58)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.45 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]